HIV Therapeutics Market To 2019 Worldwide Industry Share, Investment Trends, Growth, Size, Strategy and Forecast Research Report

Share Article

Markets Research added deep and professional market research reports on "HIV Therapeutics Market To 2019" Industry Analysis and Overview. Visit:

The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth”. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012–2019 forecast period to reach $16.3 billion.

Browse Full Report With TOC:


The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV.

The report covers and includes:

A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosis
In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action

To Download Full Report With TOC:

Reasons to Buy

The report will enhance your decision-making capability. It will allow you to:

Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Route of HIV Transmission
2.3 Etiology
2.4 Classification of HIV-1 Subtypes
2.5 Pathophysiology
2.5.1 HIV-1 Replication Cycle
2.5.2 Mechanism of CD4 T-Cell Death
2.5.3 Latent Infection and Viral Persistence
2.6 Symptoms
2.7 Diagnosis
2.7.1 HIV Antibody Assay
2.7.2 Rapid HIV Antibody Test
2.7.3 Western Blot

To Inquiry Before Buying Report:

3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Multi-class Combinations
3.1.2 Nucleotide Reverse Transcriptase Inhibitors
3.1.3 Non-Nucleoside Reverse Transcriptase Inhibitor
3.1.4 HIV Protease Inhibitor
3.1.5 Integrase Inhibitor
3.1.6 Entry Inhibitor
3.2 Comparative Efficacy and Safety
3.2.1 Multi-class Combination

4 Pipeline for HIV
4.1 Overall Pipeline
4.2 Mechanism of Action in HIV Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate of Developmetal Pipeline
4.3.2 Clinical Trial Sizes
4.3.3 Clinical Trial Duration
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Candidates in Pipeline
4.4.1 572-Trii (dolutegravir + abacavir sulfate + lamivudine) – Shionogi-ViiV Healthcare
4.4.2 Atazanavir sulfate + cobicistat – Bristol-Myers Squibb, Gilead
4.4.3 Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide – Gilead

About Us is the most comprehensive collection of market research reports. services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact US:

Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
E: sales(at)marketresearchreports(dot)biz

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gunakesh Parmar

Sheela AK
Visit website